{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:27:38Z","timestamp":1791602858701,"version":"4.3.4"},"reference-count":183,"publisher":"Oxford University Press (OUP)","issue":"38","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Albuminuria, typically measured by urinary albumin-to-creatinine ratio, is present in nearly half of all patients with heart failure. Even at low levels, albuminuria is a well-established, independent risk marker for incident heart failure and adverse outcomes in those with pre-existing heart failure. Currently, routine urinary albumin-to-creatinine ratio screening is not universally recommended in heart failure guidelines, unlike in guidelines for Type 2 diabetes, chronic kidney disease, and hypertension. Emerging data suggest that this may limit opportunities for early detection, risk stratification, and pharmacologic intervention to improve outcomes. Clinical trials of guideline-directed therapies, including renin-angiotensin inhibitors, sodium-glucose cotransporter 2 inhibitors and finerenone show that reductions in urinary albumin-to-creatinine ratio is associated with risk reductions for cardiovascular, heart failure, and chronic kidney disease outcomes, indicating that albuminuria may function as both a marker of risk and potentially a modifiable factor. This review evaluates the role of albuminuria in predicting heart failure development and progression, its potential as a modifiable risk factor, approaches for measurement, current guideline recommendations for testing, and how heart failure therapies influence albuminuria and associated outcomes.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag426","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:10:02Z","timestamp":1778674202000},"page":"5483-5500","source":"Crossref","is-referenced-by-count":1,"title":["Albuminuria and heart failure"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7683-4720","authenticated-orcid":false,"given":"Javed","family":"Butler","sequence":"first","affiliation":[{"name":"Baylor Scott and White Research Institute , 3434 Live Oak St Ste 501, Dallas, TX 75204 ,","place":["USA"]},{"name":"Department of Medicine, University of Mississippi Medical Center , 2500 N State ST Jackson, MS 39216 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-0189","authenticated-orcid":false,"given":"Adeena","family":"Jamil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow International Medical College, Dow University of Health Sciences , Karachi ,","place":["Pakistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z I","family":"Cherney","sequence":"additional","affiliation":[{"name":"Department of Medicine, Toronto General Hospital Research Institute, University Health Network , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-8376","authenticated-orcid":false,"given":"Tazeen H","family":"Jafar","sequence":"additional","affiliation":[{"name":"Program in Health Services Research & Population Health, Duke-NUS Medical School , Singapore ,","place":["Singapore"]},{"name":"Duke Global Health Institute , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5285-0419","authenticated-orcid":false,"given":"Jeffrey M","family":"Testani","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , 3434 Live Oak St Ste 501, Dallas, TX 75204 ,","place":["USA"]},{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-6351","authenticated-orcid":false,"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[{"name":"Baylor Scott and White Research Institute , 3434 Live Oak St Ste 501, Dallas, TX 75204 ,","place":["USA"]},{"name":"Division of Cardiology, Baylor Scott and White\u2014the Heart Hospital , 1100 Allied Drive, Plano, TX 75093 ,","place":["USA"]},{"name":"Department of Medicine, Baylor College of Medicine , 702 SW H K Dodgen Loop, Temple, TX 76504 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026100911322315100_ehag426-B1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026100911322315100_ehag426-B2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/J.KINT.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2026100911322315100_ehag426-B3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jchf.2014.05.016","article-title":"Albuminuria is independently associated with cardiac remodeling, abnormal right and left ventricular function, and worse outcomes in heart failure with preserved ejection fraction","volume":"2","author":"Katz","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"The Lancet"},{"key":"2026100911322315100_ehag426-B6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ejhf.778","article-title":"The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. Reduced ejection fraction","volume":"19","author":"Nayor","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026100911322315100_ehag426-B7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure: JACC state-of-the-art review","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B8","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.665831","article-title":"Albuminuria and dipstick proteinuria for predicting mortality in heart failure: a systematic review and meta-analysis","volume":"8","author":"Liang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026100911322315100_ehag426-B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","article-title":"High-normal albuminuria and risk of heart failure in the community","volume":"58","author":"Blecker","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","article-title":"A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"103","author":"Bakris","year":"2023","journal-title":"Kidney Int"},{"key":"2026100911322315100_ehag426-B11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/nejmoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108418","article-title":"Unmet needs and opportunities for optimal management of patients with type 2 diabetes and chronic kidney disease","volume":"37","author":"Pantalone","year":"2023","journal-title":"J Diabetes Complications"},{"key":"2026100911322315100_ehag426-B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.KINT.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"key":"2026100911322315100_ehag426-B14","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1681\/ASN.2008030292","article-title":"First morning voids are more reliable than spot urine samples to assess microalbuminuria","volume":"20","author":"Witte","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026100911322315100_ehag426-B16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1053\/j.ajkd.2012.05.009","article-title":"The diagnostic accuracy of a urine albumin-creatinine ratio point-of-care test for detection of albuminuria in primary care","volume":"60","author":"McTaggart","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.5527\/wjn.v6.i4.209","article-title":"Exercise-induced albuminuria and circadian blood pressure abnormalities in type 2 diabetes","volume":"6","author":"Tankeu","year":"2017","journal-title":"World J Nephrol"},{"key":"2026100911322315100_ehag426-B18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1053\/j.ajkd.2018.04.023","article-title":"Biological variability of estimated GFR and Albuminuria in CKD","volume":"72","author":"Waikar","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1053\/j.ajkd.2013.06.016","article-title":"Day-to-day variability in spot urine albumin-creatinine ratio","volume":"62","author":"Naresh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B20","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"2026100911322315100_ehag426-B21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ajkd.2023.12.018","article-title":"Urine albumin-creatinine ratio variability in people with type 2 diabetes: clinical and research implications","volume":"84","author":"Rasaratnam","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.diabres.2012.12.010","article-title":"Monitoring young people with type 1 diabetes for diabetic nephropathy: potential errors of annual ACR testing","volume":"99","author":"Oke","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"2026100911322315100_ehag426-B23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/jdi.13761","article-title":"Visit-to-visit variability in albuminuria predicts renal function deterioration in patients with type 2 diabetes","volume":"13","author":"Lin","year":"2022","journal-title":"J Diabetes Investig"},{"key":"2026100911322315100_ehag426-B24","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"Rocco","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B25","doi-asserted-by":"publisher","first-page":"7851","DOI":"10.1038\/s41598-021-86541-3","article-title":"The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality","volume":"11","author":"Chang","year":"2021","journal-title":"Sci Rep"},{"key":"2026100911322315100_ehag426-B26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.ackd.2011.06.007","article-title":"Albuminuria and prognosis in CKD: truth be told","volume":"18","author":"Yee","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026100911322315100_ehag426-B27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.7326\/ANNALS-25-02117","article-title":"Proteinuria or albuminuria as markers of kidney and cardiovascular disease risk","volume":"179","author":"Heerspink","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026100911322315100_ehag426-B28","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1681\/ASN.2010010063","article-title":"Comparison of different measures of urinary protein excretion for prediction of renal events","volume":"21","author":"Lambers Heerspink","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2026100911322315100_ehag426-B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.ajkd.2010.12.026","article-title":"Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community","volume":"58","author":"White","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1440-1797.2010.01314.x","article-title":"Proteinuria versus albuminuria in chronic kidney disease","volume":"15","author":"Guh","year":"2010","journal-title":"Nephrology"},{"key":"2026100911322315100_ehag426-B31","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7326\/M20-0529","article-title":"Conversion of urine protein\u2013creatinine ratio or urine dipstick protein to urine albumin\u2013creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant\u2013based meta-analysis","volume":"173","author":"Sumida","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026100911322315100_ehag426-B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171106","article-title":"Comparison of urine dipstick and albumin: creatinine ratio for chronic kidney disease screening: a population-based study","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"2026100911322315100_ehag426-B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.kint.2025.10.004","article-title":"From progression to remission: a new paradigm for success in chronic kidney disease","volume":"109","author":"Tangri","year":"2025","journal-title":"Kidney Int"},{"key":"2026100911322315100_ehag426-B34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/1744666X.2025.2537446","article-title":"Advancing kidney protection in type 1 diabetes: insights from emerging therapies in type 2 diabetes and chronic kidney disease","volume":"21","author":"Kugathasan","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"2026100911322315100_ehag426-B35","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1681\/ASN.0000000752","article-title":"Rapid and simultaneous initiation of guideline-directed kidney therapies in patients with CKD and type 2 diabetes","volume":"36","author":"Rashid","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026100911322315100_ehag426-B36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.105.538132","article-title":"Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham heart study","volume":"112","author":"\u00c4rnl\u00f6v","year":"2005","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12882-016-0303-x","article-title":"Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults","volume":"17","author":"Seliger","year":"2016","journal-title":"BMC Nephrol"},{"key":"2026100911322315100_ehag426-B38","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1097\/HJH.0b013e328356c579","article-title":"Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH\/ESC risk charts","volume":"30","author":"Sehestedt","year":"2012","journal-title":"J Hypertens"},{"key":"2026100911322315100_ehag426-B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135747","article-title":"Urine albumin excretion is associated with cardiac troponin T detected with a highly sensitive assay in a community-based population","volume":"10","author":"Xiao","year":"2015","journal-title":"PLoS One"},{"key":"2026100911322315100_ehag426-B40","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.12659\/MSM.903660","article-title":"Albuminuria and endothelial dysfunction in patients with non-diabetic chronic kidney disease","volume":"23","author":"Huang","year":"2017","journal-title":"Med Sci Monit"},{"key":"2026100911322315100_ehag426-B41","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1159\/000500782","article-title":"Low-grade albuminuria is associated with left ventricular hypertrophy and diastolic dysfunction in patients with hypertension","volume":"44","author":"Wang","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"2026100911322315100_ehag426-B42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/eurheartj\/ehac528","article-title":"Albuminuria as a marker of systemic congestion in patients with heart failure","volume":"44","author":"Boorsma","year":"2023","journal-title":"Eur Heart J"},{"key":"2026100911322315100_ehag426-B43","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1097\/HJH.0000000000001674","article-title":"Microvascular endothelial dysfunction is associated with albuminuria: the Maastricht study","volume":"36","author":"Martens","year":"2018","journal-title":"J Hypertens"},{"key":"2026100911322315100_ehag426-B44","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1681\/ASN.2006111217","article-title":"Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: the Hoorn study","volume":"18","author":"Hermans","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026100911322315100_ehag426-B45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jcmg.2010.01.008","article-title":"Association between coronary artery calcification progression and microalbuminuria: the MESA study","volume":"3","author":"Defilippis","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026100911322315100_ehag426-B46","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/CIRCULATIONAHA.124.071079","article-title":"Albuminuria in cardiovascular, kidney, and metabolic disorders: a state-of-the-art review","volume":"151","author":"Claudel","year":"2025","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B47","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067386","article-title":"Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study","volume":"13","author":"Tangri","year":"2023","journal-title":"BMJ Open"},{"key":"2026100911322315100_ehag426-B48","author":"USRDS [Internet]"},{"key":"2026100911322315100_ehag426-B49","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1111\/j.1523-1755.2004.66001.x","article-title":"From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria","volume":"66","author":"de Jong","year":"2004","journal-title":"Kidney Int"},{"key":"2026100911322315100_ehag426-B50","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41581-021-00462-y","article-title":"Trajectories of kidney function in diabetes: a clinicopathological update","volume":"17","author":"Oshima","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2026100911322315100_ehag426-B51","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/MNH.0000000000001016","article-title":"Screening for chronic kidney disease: change of perspective and novel developments","volume":"33","author":"Van Mil","year":"2024","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026100911322315100_ehag426-B52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ki.2010.531","article-title":"Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts","volume":"80","author":"Gansevoort","year":"2011","journal-title":"Kidney Int"},{"key":"2026100911322315100_ehag426-B53","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/ki.2010.550","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts","volume":"79","author":"Astor","year":"2011","journal-title":"Kidney Int"},{"key":"2026100911322315100_ehag426-B54","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","article-title":"Estimated glomerular filtration rate, Albuminuria, and adverse outcomes: an individual-participant data meta-analysis","volume":"330","author":"Grams","year":"2023","journal-title":"JAMA"},{"key":"2026100911322315100_ehag426-B55","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.ajkd.2021.02.335","article-title":"Changes in GFR and Albuminuria in routine clinical practice and the risk of kidney disease progression","volume":"78","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B56","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/hr.2010.39","article-title":"Very low-grade albuminuria reflects susceptibility to chronic kidney disease in combination with cardiovascular risk factors","volume":"33","author":"Heo","year":"2010","journal-title":"Hypertens Res"},{"key":"2026100911322315100_ehag426-B57","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S0140-6736(12)61272-0","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis","volume":"380","author":"Mahmoodi","year":"2012","journal-title":"The Lancet"},{"key":"2026100911322315100_ehag426-B58","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ekir.2018.01.015","article-title":"Mild Albuminuria is a risk factor for faster GFR decline in the Nondiabetic population","volume":"3","author":"Melsom","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2026100911322315100_ehag426-B59","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s10157-017-1522-6","article-title":"High-normal albuminuria and incident chronic kidney disease in a male nondiabetic population","volume":"22","author":"Ashitani","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2026100911322315100_ehag426-B60","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M23-2814","article-title":"Association of Albuminuria with chronic kidney disease progression in persons with chronic kidney disease and Normoalbuminuria","volume":"177","author":"Verma","year":"2024","journal-title":"Ann Intern Med"},{"key":"2026100911322315100_ehag426-B61","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/nejmoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B62","doi-asserted-by":"publisher","first-page":"7440","DOI":"10.3390\/ijms26157440","article-title":"Cardiorenal syndrome: molecular pathways linking cardiovascular dysfunction and chronic kidney disease progression","volume":"26","author":"Vasquez","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026100911322315100_ehag426-B63","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ekir.2022.01.1067","article-title":"Prediction of incident heart failure in CKD: the CRIC study","volume":"7","author":"Zelnick","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026100911322315100_ehag426-B64","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"key":"2026100911322315100_ehag426-B65","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s12265-025-10699-8","article-title":"Systemic interactions in HFpEF: a multiorgan perspective on pathways and therapeutic targets","volume":"18","author":"Cui","year":"2025","journal-title":"J Cardiovasc Transl Res"},{"key":"2026100911322315100_ehag426-B66","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/nejmoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B67","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1161\/CIRCULATIONAHA.104.508465","article-title":"C-reactive protein in heart failure: Prognostic value and the effect of Valsartan","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B68","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.jchf.2023.06.031","article-title":"Interleukin-6 in patients with heart failure and preserved ejection fraction","volume":"11","author":"Alogna","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B69","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1002\/ehf2.14959","article-title":"IL-6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction","volume":"11","author":"Berger","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026100911322315100_ehag426-B70","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2009.12.045","article-title":"Inflammatory markers and incident heart failure risk in older adults","volume":"55","author":"Kalogeropoulos","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B71","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCHF.2025.102712","article-title":"Prevalence and associations of systemic inflammation in heart failure across the Spectrum of ejection fraction","volume":"14","author":"Borlaug","year":"2026","journal-title":"Heart Fail"},{"key":"2026100911322315100_ehag426-B72","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1093\/eurheartj\/ehu254","article-title":"Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction","volume":"35","author":"Gori","year":"2014","journal-title":"Eur Heart J"},{"key":"2026100911322315100_ehag426-B73","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/CIRCHEARTFAILURE.109.931451","article-title":"Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction","volume":"4","author":"Westermann","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2026100911322315100_ehag426-B74","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.jacc.2019.12.069","article-title":"Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction","volume":"75","author":"Chirinos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B75","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/eurjhf\/hfs001","article-title":"Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study","volume":"14","author":"Miura","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026100911322315100_ehag426-B76","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ejhf.746","article-title":"Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure","volume":"19","author":"Sokolski","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026100911322315100_ehag426-B77","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1002\/ejhf.70079","article-title":"Urinary markers in heart failure \u2013 types, timing and thresholds","volume":"27","author":"Kobayashi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026100911322315100_ehag426-B78","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/ehf2.14920","article-title":"Loop diuretics in heart failure: the objective markers to guide the therapy are needed","volume":"11","author":"Biegus","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026100911322315100_ehag426-B79","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"key":"2026100911322315100_ehag426-B80","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B81","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/ejhf.785","article-title":"Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure","volume":"19","author":"Voors","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026100911322315100_ehag426-B82","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1161\/CIRCULATIONAHA.119.042685","article-title":"Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes Mellitus","volume":"140","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B83","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.006904","article-title":"Kidney disease biomarkers improve heart failure risk prediction in the general population","volume":"13","author":"Nowak","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026100911322315100_ehag426-B84","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cardfail.2021.10.007","article-title":"Ten-year risk-prediction equations for incident heart failure hospitalizations in chronic kidney disease: findings from the chronic renal insufficiency cohort study and the multi-ethnic study of atherosclerosis","volume":"28","author":"Mehta","year":"2022","journal-title":"J Card Fail"},{"key":"2026100911322315100_ehag426-B85","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.2337\/dc19-0587","article-title":"Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score","volume":"42","author":"Segar","year":"2019","journal-title":"Diabetes Care"},{"key":"2026100911322315100_ehag426-B86","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/clc.23298","article-title":"A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus","volume":"43","author":"Williams","year":"2020","journal-title":"Clin Cardiol"},{"key":"2026100911322315100_ehag426-B87","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-023-01796-6","article-title":"Elevated urine albumin-to-creatinine ratio increases the risk of new-onset heart failure in patients with type 2 diabetes","volume":"22","author":"Tao","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026100911322315100_ehag426-B88","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1002\/EHF2.14811","article-title":"Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction","volume":"11","author":"Min","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026100911322315100_ehag426-B89","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.jacc.2007.12.048","article-title":"Novel metabolic risk factors for incident heart failure and their relationship with obesity. The MESA (multi-ethnic study of Atherosclerosis)","volume":"51","author":"Bahrami","year":"2008","journal-title":"Study. J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B90","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"J Am Med Assoc"},{"key":"2026100911322315100_ehag426-B91","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/eurheartj\/ehm130","article-title":"Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men","volume":"28","author":"Ingelsson","year":"2007","journal-title":"Eur Heart J"},{"key":"2026100911322315100_ehag426-B92","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B93","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.041185","article-title":"Association of Albuminuria with 1-year risk of heart failure and other adverse outcomes in atrial fibrillation","volume":"14","author":"Odutayo","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"2026100911322315100_ehag426-B94","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.amjcard.2023.09.048","article-title":"Joint association of albuminuria and left ventricular hypertrophy with incident heart failure in adults at high risk with hypertension: a systolic blood pressure intervention trial substudy","volume":"208","author":"Ahmad","year":"2023","journal-title":"Am J Cardiol"},{"key":"2026100911322315100_ehag426-B95","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/HEARTJNL-2024-324988","article-title":"Prognostic impact of albuminuria in early-stage chronic kidney disease on cardiovascular outcomes: a cohort study","volume":"111","author":"Yaqoob","year":"2025","journal-title":"Heart"},{"key":"2026100911322315100_ehag426-B96","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/ejhf.2925","article-title":"Trajectories of renal biomarkers and new-onset heart failure in the general population: findings from the PREVEND study","volume":"25","author":"Sakaniwa","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026100911322315100_ehag426-B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/EURJPC\/ZWAF699","article-title":"Longitudinal trajectories of albuminuria and risk of subclinical and clinical heart failure, atrial fibrillation, and coronary heart disease: the MESA study","author":"Masrouri","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"2026100911322315100_ehag426-B98","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamacardio.2017.4987","article-title":"Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction","volume":"3","author":"de Boer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026100911322315100_ehag426-B99","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jchf.2019.01.016","article-title":"Association of urine albumin excretion with incident heart failure hospitalization in community-dwelling adults","volume":"7","author":"Bailey","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B100","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","article-title":"Incidence and epidemiology of new onset heart failure with preserved vs. Reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND","volume":"34","author":"Brouwers","year":"2013","journal-title":"Eur Heart J"},{"key":"2026100911322315100_ehag426-B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/aje\/kws447","article-title":"Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: pooled analysis of 39,000 individuals from 7 cohort studies in Japan","volume":"178","author":"Nagata","year":"2013","journal-title":"Am J Epidemiol"},{"key":"2026100911322315100_ehag426-B102","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.119.041886","article-title":"Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary","volume":"141","author":"Shah","year":"2020","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B103","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of Albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026100911322315100_ehag426-B104","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jchf.2024.11.007","article-title":"Outcomes of KDIGO-defined CKD in U.S. Veterans with HFpEF, HFmrEF, and HFrEF","volume":"13","author":"Patel","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B105","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cjca.2019.09.001","article-title":"Albuminuria: associated with heart failure severity and impaired clinical outcomes","volume":"36","author":"Shuvy","year":"2020","journal-title":"Can J Cardiol"},{"key":"2026100911322315100_ehag426-B106","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/S12933-025-02708-6","article-title":"Temporal prevalence and prognostic impact of diabetes mellitus and albuminuria in heart failure with preserved ejection fraction","volume":"24","author":"Vranken","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"2026100911322315100_ehag426-B107","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1007\/s00380-022-02025-y","article-title":"Urine albumin-to-creatinine ratio on admission predicts early rehospitalization in patients with acute decompensated heart failure","volume":"37","author":"Matsumoto","year":"2022","journal-title":"Heart Vessels"},{"key":"2026100911322315100_ehag426-B108","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1002\/ehf2.13399","article-title":"Elevated urinary albumin concentration predicts worse clinical outcomes in hospitalized acute decompensated heart failure patients","volume":"8","author":"Wang","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026100911322315100_ehag426-B109","doi-asserted-by":"publisher","first-page":"703","DOI":"10.36660\/abc.20201144","article-title":"Microalbuminuria and its prognostic significance in patients with acute heart failure with preserved, mid-range, and reduced ejection fraction","volume":"118","author":"Alata\u015f","year":"2022","journal-title":"Arq Bras Cardiol"},{"key":"2026100911322315100_ehag426-B110","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/nejmoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B111","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B112","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S2213-8587(15)00469-6","article-title":"Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial","volume":"4","author":"Heerspink","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100911322315100_ehag426-B113","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B114","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016976","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the empa-reg outcome trial","volume":"9","author":"Waijer","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026100911322315100_ehag426-B115","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/nejmoa2004967","article-title":"Cardiovascular outcomes with Ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B116","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus: results from the CANVAS program","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B117","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1681\/ASN.2020050723","article-title":"Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the credence trial","volume":"31","author":"Oshima","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026100911322315100_ehag426-B118","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B119","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B120","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/Albuminuria in chronic kidney disease and diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B121","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/J.JACC.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B122","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/nejmoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B123","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2337\/diacare.23.3.377","article-title":"Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction","volume":"23","author":"Capes","year":"2000","journal-title":"Diabetes Care"},{"key":"2026100911322315100_ehag426-B124","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B125","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/nejmoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B126","doi-asserted-by":"publisher","first-page":"542","DOI":"10.7326\/0003-4819-138-7-200304010-00010","article-title":"Cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy","volume":"138","author":"Berl","year":"2003","journal-title":"Ann Intern Med"},{"key":"2026100911322315100_ehag426-B127","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/dom.12600","article-title":"Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2026100911322315100_ehag426-B128","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"2026100911322315100_ehag426-B129","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026100911322315100_ehag426-B130","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jchf.2018.02.017","article-title":"Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure","volume":"6","author":"Mullens","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B131","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1161\/01.HYP.0000190585.54734.48","article-title":"Differential effects of \u03b2-blockers on albuminuria in patients with type 2 diabetes","volume":"46","author":"Bakris","year":"2005","journal-title":"Hypertension"},{"key":"2026100911322315100_ehag426-B132","first-page":"551","article-title":"Effect of antihypertensive treatment on qualitative estimates of microalbuminuria","volume":"10","author":"Agrawal","year":"1996","journal-title":"J Hum Hypertens"},{"key":"2026100911322315100_ehag426-B133","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1001\/jamacardio.2022.2924","article-title":"Association of empagliflozin treatment with albuminuria levels in patients with heart failure: a secondary analysis of EMPEROR-pooled","volume":"7","author":"Ferreira","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026100911322315100_ehag426-B134","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2026100911322315100_ehag426-B135","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026100911322315100_ehag426-B136","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamacardio.2023.1505","article-title":"Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone","volume":"8","author":"Agarwal","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2026100911322315100_ehag426-B137","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of Finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026100911322315100_ehag426-B138","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of Finerenone in diabetic kidney disease","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"2026100911322315100_ehag426-B139","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/nejmoa2110956","article-title":"Cardiovascular events with Finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B140","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026100911322315100_ehag426-B141","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/ndt\/gfaf116.0475","article-title":"Changes in albuminuria and the effect of finerenone on cardiovascular outcomes: insights from FINEARTS-HF","volume":"21","author":"Mc Causland","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026100911322315100_ehag426-B142","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/dom.14888","article-title":"Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta-analysis of randomized controlled trials with external adjudication of events","volume":"25","author":"Mannucci","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026100911322315100_ehag426-B143","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"The Lancet"},{"key":"2026100911322315100_ehag426-B144","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100911322315100_ehag426-B145","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B146","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/nejmoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026100911322315100_ehag426-B147","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098926","article-title":"Interaction of obesity and central obesity on elevated urinary albumin-to-creatinine ratio","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"2026100911322315100_ehag426-B148","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2337\/DC24-1773","article-title":"Tirzepatide associated with reduced albuminuria in participants with type 2 diabetes: pooled post hoc analysis from the randomized active- and placebo-controlled SURPASS-1\u20135 clinical trials","volume":"48","author":"Apperloo","year":"2025","journal-title":"Diabetes Care"},{"key":"2026100911322315100_ehag426-B149","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B150","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/J.JACC.2024.08.034","article-title":"Why has it been challenging to modify kidney disease progression in patients with heart failure?","volume":"84","author":"Vaduganathan","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B151","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.124.071110","article-title":"Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: comprehensive individual participant-level analysis of 6 randomized clinical trials","volume":"150","author":"Butt","year":"2024","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B152","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/J.JACC.2024.05.005","article-title":"Cardiovascular-kidney-metabolic overlap in heart failure with mildly reduced or preserved ejection fraction: a trial-level analysis","volume":"84","author":"Ostrominski","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B153","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/DC25-S011","article-title":"11. chronic kidney disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026100911322315100_ehag426-B154","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/J.JACC.2025.05.007","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026100911322315100_ehag426-B155","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/EURHEARTJ\/EHAE178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026100911322315100_ehag426-B156","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2026100911322315100_ehag426-B157","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2026100911322315100_ehag426-B158","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijcard.2022.06.039","article-title":"Biomarkers in heart failure: relevance in the clinical practice","volume":"363","author":"Joury","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026100911322315100_ehag426-B159","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1724600819900512","article-title":"State of the art and trends of circulating cancer biomarkers","volume":"35","author":"Gion","year":"2020","journal-title":"Int J Biol Markers"},{"key":"2026100911322315100_ehag426-B160","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/01.CIR.0000078080.37974.D2","article-title":"Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy","volume":"108","author":"Morrow","year":"2003","journal-title":"Circulation"},{"key":"2026100911322315100_ehag426-B161","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jchf.2020.03.007","article-title":"Utility of biomarkers in cardiac amyloidosis","volume":"8","author":"Pregenzer-Wenzler","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B162","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.3949\/CCJM.82.S2.05","article-title":"Biomarkers: their potential in the diagnosis and treatment of heart failure","volume":"82","author":"Heil","year":"2015","journal-title":"Cleve Clin J Med"},{"key":"2026100911322315100_ehag426-B163","doi-asserted-by":"publisher","DOI":"10.1177\/21501327211003683","article-title":"Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes Mellitus: addressing the barriers to albuminuria testing","volume":"12","author":"Christofides","year":"2021","journal-title":"J Prim Care Community Health"},{"key":"2026100911322315100_ehag426-B164","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jchf.2022.06.001","article-title":"It is time to screen for heart failure: why and how?","volume":"10","author":"Bozkurt","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026100911322315100_ehag426-B165","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ehjqcco\/qcy019","article-title":"A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure","volume":"4","author":"Nilsson","year":"2018","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026100911322315100_ehag426-B166","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.mayocpiqo.2023.07.002","article-title":"Fulfillment and validity of the kidney health evaluation measure for people with diabetes","volume":"7","author":"Ferr\u00e8","year":"2023","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2026100911322315100_ehag426-B167","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for Albuminuria in US adults at risk for chronic kidney disease","volume":"6:","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026100911322315100_ehag426-B168","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2026100911322315100_ehag426-B169","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"In: American Journal of Kidney Diseases"},{"key":"2026100911322315100_ehag426-B170","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026100911322315100_ehag426-B171","author":"ClinicalTrials.gov"},{"key":"2026100911322315100_ehag426-B172","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/HYPERTENSIONAHA.121.17323","article-title":"Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium","volume":"78","author":"Shin","year":"2021","journal-title":"Hypertension"},{"key":"2026100911322315100_ehag426-B173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110535","article-title":"Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease)","volume":"9","author":"Szczech","year":"2014","journal-title":"PLoS One"},{"key":"2026100911322315100_ehag426-B174","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14282","article-title":"Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: insights from REVEAL-CKD","volume":"54","author":"Tangri","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"2026100911322315100_ehag426-B175","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5414\/CN111106","article-title":"The drivers of non-adherence to albuminuria testing guidelines and the clinical and economic impact of not identifying chronic kidney disease","volume":"100","author":"Groehl","year":"2023","journal-title":"Clin Nephrol"},{"key":"2026100911322315100_ehag426-B176","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/1471-2369-15-64","article-title":"Primary care physicians\u2019 familiarity, beliefs, and perceived barriers to practice guidelines in non-diabetic CKD: a survey study","volume":"15","author":"Abdel-Kader","year":"2014","journal-title":"BMC Nephrol"},{"key":"2026100911322315100_ehag426-B177","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2026100911322315100_ehag426-B178","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ekir.2023.10.019","article-title":"Clinical decision support tools in the electronic medical record","volume":"9","author":"Alexiuk","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026100911322315100_ehag426-B179","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40620-022-01353-6","article-title":"The disease awareness innovation network\u201d for chronic kidney disease identification in general practice","volume":"35","author":"Pesce","year":"2022","journal-title":"J Nephrol"},{"key":"2026100911322315100_ehag426-B180","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.ekir.2025.06.031","article-title":"CKD beyond the clinic: a holistic projection of its global burden","volume":"10","author":"Faucon","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026100911322315100_ehag426-B181","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1053\/J.AJKD.2025.09.019","article-title":"Impact of smartphone-enabled home urinary albumin-to-creatinine ratio testing on Albuminuria screening and management","volume":"87","author":"Zafar","year":"2025","journal-title":"Am J Kidney Dis"},{"key":"2026100911322315100_ehag426-B182","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/S0140-6736(23)00876-0","article-title":"Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in The Netherlands (THOMAS): a prospective, randomised, open-label implementation study","volume":"402","author":"van Mil","year":"2023","journal-title":"Lancet"},{"key":"2026100911322315100_ehag426-B183","doi-asserted-by":"publisher","DOI":"10.1177\/21501319231223437","article-title":"A real-world precision medicine program including the KidneyIntelX test effectively changes management decisions and outcomes for patients with early-stage diabetic kidney disease","volume":"15","author":"Tokita","year":"2024","journal-title":"J Prim Care Community Health"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/38\/5483\/68518877\/ehag426.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/38\/5483\/68518877\/ehag426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:32:28Z","timestamp":1791559948000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/38\/5483\/8707102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":183,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag426","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,7]]},"published":{"date-parts":[[2026,6,12]]}}}